# Mass Balance and Biotransformation Study of [14C]DBPR108 in Human

> **NCT05072028** · PHASE1 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Healthy Male Subjects

## Interventions

- **DRUG:** [14C]DBPR108

## Key facts

- **NCT ID:** NCT05072028
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2021-11-28
- **Final completion:** 2021-11-28
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05072028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05072028, "Mass Balance and Biotransformation Study of [14C]DBPR108 in Human". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05072028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*